InMed Pharmaceuticals
MTRI · NASDAQ
$15.61+$4.39 (+39.14%)TodayMarket closed ·
Prev close $11.22
Who owns MTRI
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 48.5% of MTRI’s shares.
- Vivo Capital, LLC15.0%
- Adar1 Capital Management LLC14.6%
- Squadron Capital Management LLC5.9%
- Ikarian Capital LLC4.5%
- Next 6 largest institutions8.5%
- All other shareholders51.5%
| Holder | Shares | % of shares |
|---|---|---|
| Vivo Capital, LLC | 824.87K | 15.03% |
| Adar1 Capital Management LLC | 801.00K | 14.59% |
| Squadron Capital Management LLC | 325.00K | 5.92% |
| Ikarian Capital LLC | 245.03K | 4.46% |
| Ursa Fund Management, LLC | 125.80K | 2.29% |
| Montanova Capital, LLC | 100.00K | 1.82% |
| Yorkville Advisors Global, LP. | 80.37K | 1.46% |
| Boothbay Fund Management, LLC | 74.24K | 1.35% |
| Sabby Management, LLC | 44.97K | 0.82% |
| Jane Street Capital, L.L.C. | 43.08K | 0.78% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $34.57K (1 trade) of MTRI on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| ADAR1 Capital Management, LLC | Buy | 2.64K | $34.57K |
Short interest
Settled Sep 15, 2022
- Shares short
- 8.28K
- Days to cover
- 1.00
- % of shares outstanding
- 0.15%
- Average daily volume
- 572.34K
- Change since last report
- +0.0%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.